Home › Research › Mild cognitive impairment
Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau
Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative.. Frontiers in aging neuroscience, 2013-10-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results For prediction of dementia in MCI, the AD signature cortical thickness biomarker performed better than hippocampal volume. When CSF amyloid-β was dichotomized using previously published cutoff values and treated as a categorical variable, a multivariate stepwise Cox regression model indicated that both the AD signature MRI marker and the categorical CSF amyloid-β marker were useful in predicting time-to-event diagnosis of AD dementia. These results provide further support for emerging models of the temporal relationship of pathophysiologic events in AD and demonstrate the utility of these biomarkers at the prodromal stage of the illness.
What this study adds
Evidence grade: Low
This is a trial. For predicting dementia in mild cognitive impairment, an MRI measure of Alzheimer's signature cortical thickness performed better than hippocampal volume, and both this MRI marker and cerebrospinal fluid amyloid-beta were useful in predicting time to diagnosis. This is a biomarker comparison study and does not show that any treatment, cure, or prevention works.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dickerson, B. C., Wolk, D. A., & Alzheimer's Disease Neuroimaging Initiative. (2013). Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2013.00055
Vancouver
Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Frontiers in aging neuroscience. 2013. doi:10.3389/fnagi.2013.00055. PMID: 24130528.
BibTeX
@article{dickerson2013-24130528,
author = {Dickerson, B. C. and Wolk, D. A. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau}},
journal = {Frontiers in aging neuroscience},
year = {2013},
doi = {10.3389/fnagi.2013.00055},
pmid = {24130528},
url = {https://doi.org/10.3389/fnagi.2013.00055}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results For prediction of dementia in MCI, the AD signature cortical thickness biomarker performed better than hippocampal volume.
- When CSF amyloid-β was dichotomized using previously published cutoff values and treated as a categorical variable, a multivariate stepwise Cox regression model indicated that both the AD signature MRI marker and the categorical CSF amyloid-β marker were useful in predicting time-to-event diagnosis of AD dementia.
- These results provide further support for emerging models of the temporal relationship of pathophysiologic events in AD and demonstrate the utility of these biomarkers at the prodromal stage of the illness.
Why it matters
For predicting dementia in mild cognitive impairment, an MRI measure of Alzheimer's signature cortical thickness performed better than hippocampal volume, and both this MRI marker and cerebrospinal fluid amyloid-beta were useful in predicting time to diagnosis. This is a biomarker comparison study and does not show that any treatment, cure, or prevention works.
Study details
- Study designclinical trial
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 152 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.1 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 18 other studies in this library |
| Still being cited | 2 / 4 | Cited 28 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Bradford Dickerson: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24130528) |
| Free to read | 2 / 2 | Free to read |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2013.00055
- PubMed: 24130528
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 27.
Later studies that cite this one
18 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.